Table 6. Prospective randomized phase III studies of first-generation EGFR TKIs in untreated patients with advanced EGFR mutation-positive NSCLC.

Study	Population	Treatment arms	No. of pts	RR (%)	Median PFS			Median OS
					Months	HR; P		Months	HR; P
IPASS	East Asian	Gefitinib	609 [132]*	43.0 (71.2)	9.5	0.48; <0.001		21.6	1.0; 0.99
	Adeno & nonsmokers	Carbo/pacli	608 [129]*	32.2 (47.3)	6.3			21.9
First-	Korean	Gefitinib	159 [26]*	55.4 (84.6)	8.4	0.544; 0.086		22.3	0.932; 0.60
SIGNAL	Adeno & nonsmokers	Cis/gem	150 [16]*	46.0 (37.5)	6.7			22.9
WJTOG3405	Japanese	Gefitinib	86	62.1	9.2	0.489; <0.0001		35.5	1.2; 0.44
	EGFR mut	Cis/doce	86	32.2	6.3			38.8
NEJ002	Japanese	Gefitinib	114	73.7	10.8	0.30; <0.001		27.7	0.88; 0.48
	EGFR mut	Carbo/pacli	114	30.7	5.4			26.6
OPTIMAL	Chinese	Erlotinib	82	83	13.1	0.16; <0.0001		22.8	1.19; 0.26
	EGFR mut	Carbo/gem	72	36	4.6			27.2
EURTAC	European	Erlotinib	86	64	9.7	0.37; <0.0001		19.3	1.04; 0.87
	EGFR mut	Platinum CT	87	18	5.2			19.5
ENSURE	Asian	Erlotinib	110	62.7	11	0.34; <0.0001		26.3	0.91; 0.61
	EGFR mut	Cis/gem	107	33.6	5.5			25.5

*, patients with confirmed EGFR mut. EGFR, epidermal growth factor receptor; TKIs, tyrosine-kinase inhibitors; NSCLC, non-small cell lung cancer.